This story portrays a quadriplegic man who believes a stem cell transplant helped him to recover partial function after a spinal cord injury. The story effectively conveys the devastation of spinal cord injuries and correctly identifies stem cell therapy as an experimental and unproven treatment.
However, its thrust that the therapy “shows promise” is misleading; its efficacy has yet to be supported by rigorous trials. The story doesn’t give data on costs, harms, and availability that might have injected balance into the piece. We’ve reviewed other stories that unfairly wow readers up front only to save caveats for the end, including a recent BuzzFeed piece on an experimental device that restored some function to a paralysis patient. But in this case, the story also perpetuates a trend of media coverage that hypes unproven stem cell therapies for various conditions, unfairly raising patient expectations based on isolated and preliminary findings.
About 282,000 people in the U.S. are estimated to be living with spinal cord injuries, mainly from vehicle collisions and falls, according to the National Spinal Cord Injury Statistical Center. Spinal cord injuries can be incomplete, meaning that patients retain some motor or sensory function below the injury, or complete, in which there is a total lack of sensory and motor function below the level of injury. In either case, they almost always result in lifelong disability. Effective emergency care for people with spinal cord injuries and aggressive treatment and rehabilitation can minimize damage to the nervous system and restore some function. However, there is no treatment to repair spinal cord injuries.
Stem cells are an active area of research for spinal cord repair, but their potential and associated risks are not clear. According to the Canadian Stem Cell Foundation, stem cells are being studied as a source of new cells and products that could prevent further damage, restore nerve function, generate new nerve cells and guide the regrowth of severed nerve fibers. It says current trials are very small, mostly testing the safety of putting adult stem cells into patients. The question of whether stem cells can safely improve function is years away from being answered.
Meanwhile, there’s growing concern about media reports that exaggerate the potential of stem cell therapies that are in early phases of research. This month the International Society for Stem Cell Research issued guidelines to encourage accurate and balanced communication of stem cell science, including setbacks as well as progress.
The story does not address the cost of this procedure.
The story relies on comments from the patient, James Mason, and his doctor, Arthur Jenkins, M.D., a neurosurgeon at Mount Sinai Hospital in New York City. Mason is shown in video footage moving his arms and legs in physical therapy. Three months after surgery, he reports that his wrists have become stronger. Six months post-surgery, he says his improvement has “doubled,” sensation has returned to his feet and legs, and there’s slight movement in his hips. The physician, Jenkins, says: “My two cents is it worked that this actually changed his neurological recovery and function, that his actual functional improvement is from the stem cells that were injected.”
No data is presented to back up these statements. The narrator, CBS chief medical correspondent Jonathan LaPook, M.D., says the company sponsoring a trial of this therapy, which isn’t named, reported that four out of six patients it was following experienced improvement in motor strength and function. However, there are no measurements provided for any of these observed improvements.
If these patients are being followed as part of a trial, readers ought to know what outcomes the researchers are looking for (even if the trial isn’t complete as yet) and how they would objectively measure their improvement.
No harms are mentioned. Any surgical procedure presents a risk. Since clinical trials of stem cell procedures for spinal cord injury are just beginning, they carry a risk of unforeseen adverse effects.
The story presents a single anecdote as evidence of the benefits of stem cell transplants for spinal cord injury. It mentions that the case is part of a clinical trial with six patients, but does not give details such as the objective, sponsor, or limitations of the trial.
The story does not exaggerate the frequency or severity of this condition.
The story does tell viewers that the physician who performed the procedure “is not affiliated with the company” sponsoring the trial. However, it should have included an independent expert and named the trial sponsor.
There is no discussion of alternative therapies or avenues of research for spinal cord injuries.
The story states that the treatment is experimental, and correspondent LaPook acknowledges at the end, “More research will be needed to try to establish whether (stem cells) actually repair damage to the spinal cord.” But that strikes us as too little, too late. The story does not explain that it takes years to gain FDA approval for a new treatment, and many therapies particularly in the stem cell field never reach the finish line due to cost, safety, and efficacy hurdles.
The story does not misrepresent the novelty of the procedure.
However, we would have liked to read a bit more about how stem cells are being used (experimentally) for other related medical applications.
The story does not appear to rely on a news release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments (1)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Geoff Holt
May 28, 2016 at 7:03 amGood article. this media “frenzy” is nothing new. For years the media latch onto unproven technologies and untested science to falsely raise the hopes of those living with SCI. It is irresponsible. Read an article I wrote a few years ago http://geoffholt.com/2014/10/paralysis-an-open-letter/
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like